COVID-19 Delays Confirmation Of Bedoya, A Key Vote In FTC Probe Of PBMs

By John Wilkerson / April 27, 2022 at 3:00 PM
Coronavirus infections in the Senate will likely delay confirmation of a Federal Trade Commission nominee who could break a tie vote that blocked an FTC probe of pharmacy benefit managers’ impact on drug prices. In a party-line, 2-2 vote, the Federal Trade Commission in February declined to undertake the inquiry into PBM business practices . Bedoya’s confirmation would tip the commission’s makeup in favor of Democratic appointees. “So believe me Democrats want to get Mr. Bedoya appointed as soon as...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.